A 15-year-old boy had hypercalcemia in association with malignant retroperitoneal paraganglioma. He had suppressed circulating levels of intact parathyroid hormone, whereas parathyroid hormone-related protein (PTHrP) immunoreactivity was elevated in plasma. Both the serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels were normal. Preoperatively the patient required control of hypercalcemia with intravenous pamidronate therapy. His circulating calcium and PTHrP concentrations became normal after a successful surgical resection of the primary retroperitoneal tumor. To our knowledge, this is the first reported case of elevated PtHrP levels in a patient with paraganglioma which resolved postoperatively.

Ali IM, Graham C, Sanalla B, Bell D: Carotid body tumor associated with hyperparathyroidism. Ann Vasc Surg 1994;8:595–598.
White MC, Hickson BR: Multiple paragangliomata secreting catecholamines and calcitonin with intermittent hypercalcaemia. J R Soc Med 1979;72:532–538.
Passwell J, Boichis H, Lotan D, David R, Theodor R, Cohen BE, Many M: The metabolic effects of excess noradrenaline secretion from a pheochromocytoma. Am J Dis Child 1977;131:1011–1014.
Stewart AF, Hoecker JL, Mallette LE, Segre GV, Amatruda TT Jr, Vignery A: Hypercalcemia in pheochromocytoma. Evidence for a novel mechanism. Ann Intern Med 1985;102:776–779.
Burtis WJ, Wu T, Bunch C, Wysolmerski JJ, Insogna KL, Weir EC, Broadus AE, Stewart AF: Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem 1987;262:7151–7156.
Moseley JM, Kubota M, Diefenbach-Jagger H, Wettenhall RE, Kemp BE, Suva LJ, Rodda CP, Ebeling PR, Hudson PJ, Zajac JD, et al: Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci USA 1987;84:5048–5052.
Strewler GJ, Stern PH, Jacobs JW, Eveloff J, Klein RF, Leung SC, Rosenblatt M, Nissenson RA: Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. J Clin Invest 1987;80:1803–1807.
Kimura S, Nishimura Y, Yamaguchi K, Nagasaki K, Shimada K, Uchida H: A case of pheochromocytoma producing parathyroid-related protein and presenting with hypercalcemia. J Clin Endocrinol Metab 1990;70:1559–1563.
Bridgewater JA, Ratcliffe WA, Bundred NJ, Owens CWI: Malignant phaeochromocytoma and hypercalcaemia. Postgrad Med J 1993;69:77–79.
Suva LJ, Winslow GA, Wettenhall REH, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY, et al: A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987;237:893–896.
Juppner H, Abou-Samra AB, Freeman M, Kong XF, Schipani E, Richards J, Kolakowski LF Jr, Hock J, Potts JT Jr, Kronenberg MM, et al: A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991;254:1024–1026.
Budayr AA, Nissenson RA, Klein RF, Pun KK, Clark OH, Diep D, Arnaud CD, Strewler GJ: Increased levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia. Ann Intern Med 1989;111:807–812.
Burtis WJ, Brady TG, Orloff JJ, Ersbak JB, Warrell RP Jr, Olson BR, Wu TL, Mitnick BE, Broadus AE, Stewart AF: Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990;322:1106–1112.
Grill V, Ho P, Body JJ, Johanson N, Lee SC, Kukreja SC, Moseley JM, Martin TJ: Parathyroid hormone-related protein: Elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 1991;73:1309–1315.
Mune T, Katakami H, Kato Y, Yasuda K, Matsukara S, Miura K: Production and secretion of parathyroid hormone-related protein in pheochromocytoma: Participation of an α-adrenergic mechanism. J Clin Endocrinol Metab 1993;76:757–762.
Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE: Biochemical evaluation of patients with cancer-associated hypercalcemia. Evidence for humoral and nonhumoral groups. N Engl J Med 1980;303:1377–1383.
Schilling T, Pecherstorfer M, Blind E, Leidig G, Ziegler R, Raue F: Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab 1993;76:801–803.
Schweitzer DH, Hamdy NAT, Frolich M, Zwinderman AH, Papapoulos SE: Malignancy-associated hypercalcemia: resolution of controversies over vitamin D metabolism by a pathophysiological approach to the syndrome. Clin Endocrinol 1994;41:251–256.
Wimalawansa SJ: Hypercalcaemia in malignancy: aetiology, pathophysiology, and its clinical management. Rev Endocr Rel Cancer 1993;45:5–24.
Gurney H, Grill V, Martin TJ: Parathyroid hormone-related protein and response to pamidronate in tumor-induced hypercalcaemia. Lancet 1993;341:1611–1613.
Wimalawansa SJ: Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with biphosphonate. Cancer 1994;73:2223–2230.
Walls J, Ratcliffe WA, Howell A, Bundred NJ: Response to intravenous biphosphonate therapy in hypercalcemic patients with and without bone metastases: The role of parathyroid hormone-related protein. Br J Cancer 1994;70:169–172.
Pecherstorfer M, Schilling T, Blind E, Zimmer-Roth I, Baumgartner G, Ziegler R, Raue F: Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab 1994;78:1268–1270.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.